First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry

BACKGROUND: The biolimus-eluting stent (BES) was the first to elute anti-proliferative drug from a biodegradable polymer. In the randomized LEADERS trial, a stainless steel BES showed non-inferior efficacy compared to a sirolimus-eluting stent and a long-term safety advantage. We report the first cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Menown, Ian B.A., Mamas, Mamas A., Cotton, James M., Hildick-Smith, David, Eberli, Franz R., Leibundgut, Gregor, Tresukosol, Damras, Macaya, Carlos, Copt, Samuel, Sadozai Slama, Sara, Stoll, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046540/
https://www.ncbi.nlm.nih.gov/pubmed/32140552
http://dx.doi.org/10.1016/j.ijcha.2020.100472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046540/
https://www.ncbi.nlm.nih.gov/pubmed/32140552
http://dx.doi.org/10.1016/j.ijcha.2020.100472

Ejemplares similares